FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4213304556> ?p ?o ?g. }

• W4213304556 endingPage "TPS592" @default.
• W4213304556 startingPage "TPS592" @default.
• W4213304556 abstract "TPS592 Background: Adoptive cellular therapies can lead to durable responses in treatment refractory leukemias and lymphomas; however, these approaches are still in early stage development for metastatic solid tumors. FH-MagIC TCR-T is an autologous CD8+ and CD4+ T cell product transduced with a transgenic T cell receptor (TCR) targeting MAGE-A1. MAGE-A proteins are classified within the “testis restricted” cancer testis antigens and are broadly expressed in a wide range of malignancies, including urothelial carcinomas, triple negative breast cancers (TNBCs) and non-small cell lung cancers (NSCLCs). Importantly, MAGE-A1 is undetectable in most normal tissues exclusive of the immune privileged testes, thereby making MAGE-A1 an ideal target for T cell immunotherapy approaches. Of note, FH-MagIC TCR-T is specific to the Class I HLA A*02:01-restricted MAGE-A1 epitope. Based on preclinical studies testing FH-MagIC-T in MAGE-A1 expressing tumor models, we have launched a Phase I/II study evaluating this autologous transgenic TCR therapy. Methods: This is a Phase I/II study testing FH-MagIC TCR-T cells in patients with metastatic urothelial carcinoma, TNBC or NSCLC. Eligible patients must have HLA type HLA-A*02:01 and demonstrate expression of MAGE-A1 on archival tumor tissue (≥1+ by immunohistochemistry). Patients must have been offered or received: i) anti-PD(L)1 therapy; ii) enfortumab vedotin (urothelial carcinoma patients); and iii) FDA-approved targeted therapies (e.g. NSCLC patients with actionable mutations in EGFR, ROS1, etc.). For each dose level (DL) in the Phase 1 portion, 1 patient will be treated without lymphodepletion (LD). If no dose limiting toxicities (DLT) are observed, the next 3 patients will receive LD with cyclophosphamide 300mg/m 2 and fludarabine 30mg/m 2 IV days -4 to -2 before T cell infusion. The first 4 patients will be treated at DL1: 1 x 10 9 cells. If no DLTs are observed, the next 4 patients will be treated at DL2: 5 x 10 9 cells. Otherwise, if a DLT is observed at DL1, the next 4 patients will be treated at DL-1: 5 x 10 8 cells. The Phase 2 portion of the trial will test FH-MagIC-TCR T cell product at the RP2D with the addition of standard of care anti-PD(L)1 therapy. Primary objectives are to assess safety (Phase 1) and radiographic response rate (Phase 2) per RECIST v1.1. Secondary objectives will evaluate progression free survival, overall survival, persistence of transgenic T cells in peripheral blood and migration into tumor tissue. For the Phase 2 portion, we assume a 5% null response rate (H0). If the true response rate with TCR-transduced cells is 25% (H1), 15 patients will yield 84% power at a one-sided alpha =.05. Clinical trial information: NCT04639245." @default.
• W4213304556 created "2022-02-24" @default.
• W4213304556 creator A5005666925 @default.
• W4213304556 creator A5014339741 @default.
• W4213304556 creator A5023949296 @default.
• W4213304556 creator A5029519880 @default.
• W4213304556 creator A5035086451 @default.
• W4213304556 creator A5036480949 @default.
• W4213304556 creator A5039484460 @default.
• W4213304556 creator A5044945918 @default.
• W4213304556 creator A5053281028 @default.
• W4213304556 creator A5062975081 @default.
• W4213304556 creator A5064100640 @default.
• W4213304556 creator A5073301255 @default.
• W4213304556 date "2022-02-20" @default.
• W4213304556 modified "2023-10-03" @default.
• W4213304556 title "Attamage-A1: Phase I/II study of autologous CD8+ and CD4+ transgenic t cells expressing high affinity MAGE-A1-specific T-cell receptor (TCR) combined with anti-PD(L)1 in patients with metastatic MAGE-A1 expressing cancer." @default.
• W4213304556 doi "https://doi.org/10.1200/jco.2022.40.6_suppl.tps592" @default.
• W4213304556 hasPublicationYear "2022" @default.
• W4213304556 type Work @default.
• W4213304556 citedByCount "1" @default.
• W4213304556 countsByYear W42133045562022 @default.
• W4213304556 crossrefType "journal-article" @default.
• W4213304556 hasAuthorship W4213304556A5005666925 @default.
• W4213304556 hasAuthorship W4213304556A5014339741 @default.
• W4213304556 hasAuthorship W4213304556A5023949296 @default.
• W4213304556 hasAuthorship W4213304556A5029519880 @default.
• W4213304556 hasAuthorship W4213304556A5035086451 @default.
• W4213304556 hasAuthorship W4213304556A5036480949 @default.
• W4213304556 hasAuthorship W4213304556A5039484460 @default.
• W4213304556 hasAuthorship W4213304556A5044945918 @default.
• W4213304556 hasAuthorship W4213304556A5053281028 @default.
• W4213304556 hasAuthorship W4213304556A5062975081 @default.
• W4213304556 hasAuthorship W4213304556A5064100640 @default.
• W4213304556 hasAuthorship W4213304556A5073301255 @default.
• W4213304556 hasConcept C121608353 @default.
• W4213304556 hasConcept C126322002 @default.
• W4213304556 hasConcept C147483822 @default.
• W4213304556 hasConcept C154317977 @default.
• W4213304556 hasConcept C167672396 @default.
• W4213304556 hasConcept C19317047 @default.
• W4213304556 hasConcept C202751555 @default.
• W4213304556 hasConcept C203014093 @default.
• W4213304556 hasConcept C2776090121 @default.
• W4213304556 hasConcept C2777701055 @default.
• W4213304556 hasConcept C502942594 @default.
• W4213304556 hasConcept C55493867 @default.
• W4213304556 hasConcept C71924100 @default.
• W4213304556 hasConcept C86803240 @default.
• W4213304556 hasConcept C8891405 @default.
• W4213304556 hasConceptScore W4213304556C121608353 @default.
• W4213304556 hasConceptScore W4213304556C126322002 @default.
• W4213304556 hasConceptScore W4213304556C147483822 @default.
• W4213304556 hasConceptScore W4213304556C154317977 @default.
• W4213304556 hasConceptScore W4213304556C167672396 @default.
• W4213304556 hasConceptScore W4213304556C19317047 @default.
• W4213304556 hasConceptScore W4213304556C202751555 @default.
• W4213304556 hasConceptScore W4213304556C203014093 @default.
• W4213304556 hasConceptScore W4213304556C2776090121 @default.
• W4213304556 hasConceptScore W4213304556C2777701055 @default.
• W4213304556 hasConceptScore W4213304556C502942594 @default.
• W4213304556 hasConceptScore W4213304556C55493867 @default.
• W4213304556 hasConceptScore W4213304556C71924100 @default.
• W4213304556 hasConceptScore W4213304556C86803240 @default.
• W4213304556 hasConceptScore W4213304556C8891405 @default.
• W4213304556 hasIssue "6_suppl" @default.
• W4213304556 hasLocation W42133045561 @default.
• W4213304556 hasOpenAccess W4213304556 @default.
• W4213304556 hasPrimaryLocation W42133045561 @default.
• W4213304556 hasRelatedWork W2016887421 @default.
• W4213304556 hasRelatedWork W2033962007 @default.
• W4213304556 hasRelatedWork W2045231844 @default.
• W4213304556 hasRelatedWork W2055715607 @default.
• W4213304556 hasRelatedWork W2063492259 @default.
• W4213304556 hasRelatedWork W2106875608 @default.
• W4213304556 hasRelatedWork W2181431303 @default.
• W4213304556 hasRelatedWork W2287738525 @default.
• W4213304556 hasRelatedWork W4229027259 @default.
• W4213304556 hasRelatedWork W4254282151 @default.
• W4213304556 hasVolume "40" @default.
• W4213304556 isParatext "false" @default.
• W4213304556 isRetracted "false" @default.
• W4213304556 workType "article" @default.